Protagonist Therapeutics

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Initiated Phase 3 VERIFY study of rusfertide in polycythemia vera, reaffirming rusfertide in PV as the Company's primary point of focus Presented topline results from the Phase 2 IDEAL study of PN-943 in ulcerative colitis with consistent treatment effects at the lower 150 mg BID dose across key endpoints; formally engaged PJT Partners to lead external partnering efforts Milestone payment of $25 million received from Janssen upon dosing of third patient in the Phase 2B FRONTIER-1 study of PN-235 in psoriasis NEWARK, Calif. , May 4, 2022 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today reported financial results for the first quarter of 2022 ended March 31, 2022 and provided a corporate update.

Protagonist Reports First Quarter 2022 Financial Results and Provides Corporate Update

Los Angeles, California--(Newsfile Corp. - April 29, 2022) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Protagonist Therapeutics, Inc. ("Protagonist Therapeutics" or "the Company") (NASDAQ: PTGX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Protagonist Therapeutics disclosed in an April 13, 2022, SEC filing...

Investigation Alert: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - April 28, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Protagonist Therapeutics, Inc. ("Protagonist Therapeutics" or "the Company") (NASDAQ: PTGX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Protagonist Therapeutics disclosed in an April 13, 2022, SEC filing...

Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - April 27, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Protagonist Therapeutics, Inc. ("Protagonist Therapeutics" or "the Company") (NASDAQ: PTGX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Protagonist Therapeutics disclosed in an April 13, 2022, SEC filing...

Ongoing Investigation Alert: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Protagonist Therapeutics Inc (NASDAQ: PTGX) announced topline results from the Phase 2 IDEAL study of PN-943 in moderate-to-severe ulcerative colitis (UC) patients. 159 patients with moderate-to-severe active UC were randomized to either twice daily (BID) with 450 mg or 150 mg PN-.

Why Protagonist Therapeutics Shares Are Crashing Today

Los Angeles, California--(Newsfile Corp. - April 26, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Protagonist Therapeutics, Inc. ("Protagonist Therapeutics" or "the Company") (NASDAQ: PTGX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Protagonist Therapeutics disclosed in an April 13, 2022, SEC filing...

Investigation Reminder: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Shares of Protagonist Therapeutics Inc. PTGX, -0.58% tumbled 30.8% in premarket trading on Tuesday the day after the company said a Phase 2 clinical trial that gave patients a higher dose of its experimental ulcerative colitis treatment did not meet the primary endpoint. However, using a lower dose demonstrated clinical remission among some patients, and Protagonist said it plans to move forward with a Phase 3 clinical trial using this dosing.

Protagonist Therapeutics shares slid after sharing Phase 2 data for its experimental ulcerative colitis treatment

PN-943 achieved 27.5% clinical remission with a delta of 13% versus placebo, with strong concordance across all key proxies including histological and endoscopic endpoints for efficacy, in the twice daily 150 mg dose arm Achieved clinical proof-of-concept and validation for oral, gut-restricted approach for ulcerative colitis via blockade of the alpha-4-beta-7-integrin pathway  Plans underway for a registrational Phase 3 study anchored around twice daily 150 mg dose of PN-943, pending regulatory guidance Protagonist to host a conference call today at 6:00 p.m. ET NEWARK, Calif.

Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis

Los Angeles, California--(Newsfile Corp. - April 25, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Protagonist Therapeutics, Inc. ("Protagonist Therapeutics" or "the Company") (NASDAQ: PTGX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Protagonist Therapeutics disclosed in an April 13, 2022, SEC filing...

Ongoing Investigation Notice: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , April 24, 2022 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) resulting from allegations that Protagonist Therapeutics may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Protagonist Therapeutics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

TOP RANKED ROSEN LAW FIRM Encourages Protagonist Therapeutics, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - PTGX

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) resulting from allegations that Protagonist Therapeutics may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Protagonist Therapeutics securities you may be entitled to compensation without payment of any out of pocket fees or

EQUITY ALERT: Rosen Law Firm Encourages Protagonist Therapeutics, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – PTGX

Protagonist Therapeutics Inc (NASDAQ: PTGX) received a letter from the FDA indicating the agency's intent to rescind Breakthrough Therapy Designation for the company's rusfertide product candidate in polycythemia vera.  Polycythemia vera is a type of blood cancer.

FDA Intends To Revoke Protagonist Therapeutics' Rusfertide Breakthrough Tag In Rare Form Of Blood Cancer

VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announces the appointment of Don Kalkofen as Chief Financial Officer (CFO) to replace Jeremy Wright. Mr. Wright will continue to assist the Company in a consulting capacity. Mr. Kalkofen brin

Alpha Cognition Announces Change of CFO, Grant of Stock Options and Addition to the Board of Directors

NEWARK, Calif., March 28, 2022 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) today announced the appointment of Asif Ali as Executive Vice President and Chief Financial Officer (CFO).

Protagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President and Chief Financial Officer

Phase 2b clinical trial of PN-235, an oral IL-23 receptor antagonist, has launched with a target enrollment of 240 patients NEWARK, Calif., March 16, 2022 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") announced today earning a $25 million milestone payment from its collaboration with Janssen Biotech, Inc. (Janssen), following dosing of the third patient in the Phase 2b FRONTIER 1 clinical trial of PN-235 (JNJ-77242113).

Protagonist Therapeutics Earns $25 Million Milestone Payment from Janssen Biotech for Dosing of Third Patient in Phase 2b Clinical Trial of PN-235 in Moderate-to-Severe Plaque Psoriasis

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 2.53% and 16.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Protagonist Therapeutics (PTGX) Reports Q4 Loss, Tops Revenue Estimates

NEWARK, Calif., Feb. 28, 2022 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.

Protagonist Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

Harmony Biosciences Holdings

Schrodinger 

Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider.

3 Desirable Drug Stocks With Very Promising Pipelines

Protagonist Therapeutics (PTGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Protagonist Therapeutics (PTGX) Soars 5%: Is Further Upside Left in the Stock?

NEWARK, Calif., Feb. 10, 2022 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V.

Protagonist Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Protagonist Therapeutics is currently working to tackle some serious issues with an underserved form of blood cancer. A recent cancer scare sent shockwaves through the company's valuation, and it has been almost entirely resolved.

Protagonist Is Still Being Undervalued Like There's Real Risk

NEWARK, Calif., Jan. 4, 2022 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V.

Protagonist Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

NEWARK, Calif., Dec. 12, 2021 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today presented updated data from two ongoing Phase 2 studies evaluating rusfertide in patients with polycythemia vera (PV), demonstrating its ability to essentially eliminate the need for phlebotomies in patients.

Protagonist Therapeutics Presents Updated Phase 2 Rusfertide Data in Polycythemia Vera (PV) at ASH 2021 Annual Meeting

Protagonist Therapeutics Inc (NASDAQ: PTGX) has selected PN-235 (JNJ-77242113) as the final candidate for all clinical studies in multiple indications based on the intervention of the Interleukin-23 (IL-23) pathway, under its collaboration with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE: JNJ).  In addition to the previously announced Phase 2 study of PN-235 in psoriasis, new Phase 2 studies of PN-235 in inflammatory bowel diseases (IBD) will commence in late 2022.

Protagonist To Go Ahead With Oral Peptide PN-235, Discontinues Phase 1 Candidate

NEWARK, Calif., Dec. 3, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V.

News for Protagonist Therapeutics Stock (PTGX)